5-Hydroxytryptophan and carbidopa in spontaneously hypertensive rats.
Serial measurements of blood pressure, body weight, food and water intake, and salt and water excretion were compared in two groups of spontaneously hypertensive rats (SHR) over a 12-day period: control SHR (n = 11) and a group (n = 9) which received supplementary 5-hydroxytryptophan (5-HTP; 2 mg/ml) in its drinking water. During the final 4 days of study, both groups received additional oral carbidopa (50 mg/kg twice a day) to inhibit peripheral, but not brain aromatic L-amino-acid decarboxylase (LAAD), an enzyme necessary to the formation of 5-hydroxytryptamine (5-HT, serotonin) from 5-HTP. 5-Hydroxytryptophan increased urinary 5-HT and its metabolite 5-hydroxyindoleacetic acid (5-HIAA) markedly; following carbidopa, urinary 5-HT, and to a lesser degree urinary 5-HIAA, decreased, whereas brain 5-HT and 5-HIAA increased. Spontaneously hypertensive rats treated with 5-HTP plus carbidopa had significantly lower blood pressure levels, lower pulse rates, reductions in food and water intake, salt and water excretion, and a loss of body weight, when compared with the control SHR. These data indicate that enhanced brain formation of 5-HT can give rise to metabolic and circulatory responses with a resultant lowering of blood pressure.
Itskovitz
H D
HD
Department of Medicine, New York Medical College, Valhalla 10595.
Werber
J L
JL
Sheridan
A M
AM
Brewer
T F
TF
Stier
C T
CT
D006916:5-Hydroxytryptophan / Q000627:therapeutic use*; D000818:Animals; D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D001794:Blood Pressure; D001921:Brain / Q000378:metabolism; D002230:Carbidopa / Q000627:therapeutic use*; D006973:Hypertension / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D051381:Rats; D011918:Rats, Inbred SHR; D012701:Serotonin / Q000378:metabolism; D015431:Weight Loss
D065105:Aromatic Amino Acid Decarboxylase Inhibitors; D012701:Serotonin; D006916:5-Hydroxytryptophan; D002230:Carbidopa